Please login to the form below
Kisplyx
This page shows the latest Kisplyx news and features for those working in and with pharma, biotech and healthcare.
NICE gives green light to Ipsen's Cabometyx
Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
Latest news
-
Eisai wins EU licence for kidney cancer drug Kisplyx
Under brand name Lenvima, Kisplyx was granted US marketing authorisation in May this year, the drug having received breakthrough and priority review status by the FDA. ... Analysts are now suggesting that with Kisplyx's approval in two key markets, plus
-
HIV prevention pill heads July CHMP recommendations
Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx. ... The panel also recommended approval of two targeted kidney cancer medicines - Ipsen Pharma's Cabometyx (cabozantinib) and Eisai's Kisplyx (lenvatinib
Eisai wins EU licence for kidney cancer drug Kisplyx
HIV prevention pill heads July CHMP recommendations
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital strategist
-
Competitive
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- GSK reveals plans for £400m R&D facility expansion in England
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
